Bullish
$ADMA One additional observation: the recent announcement by ADMA management of the Partnership for Contract Revenues being added to the Revenue Stream from the selling of "Blood Fractions", is highly significant . These are essentially the elements derived from the Blood that are not currently being used by ADMA for their 3 separate FDA Approved Products; essentially they were previously Raw Material Waste. Hence, the Cost of Goods Sold, for the materials to develop end products from those essential Blood Fraction elements, by selling to a Partner what was once waste materials from existing inventory, means that the resulting revenues will be a notable high margin contribution to the bottom line going forward.
  • 10
  • 4